Immutep’s Phase III TACTI-004 trial of eftilagimod alfa (efti) in first-line non‑small‑cell lung cancer was halted after an independent data monitoring committee recommended stopping for futility. The sponsor disclosed the decision following an interim analysis, prompting a dramatic market reaction and an immediate program reassessment. The readout contrasts with prior positive signals for efti in earlier cohorts and leaves the company poring over datasets to identify drivers of the failure. Immutep CEO Marc Voigt said the team is “disappointed and surprised” and will undertake a comprehensive review to decide next steps. Investors have already repriced the company, underscoring execution and late‑stage risk in immuno‑oncology development.